ClinicaliQ Trial Snapshot
- A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07690059.
- What is being tested: SC0032, a magnesium salt oral spray formulation, is being evaluated in a randomized placebo-controlled trial to assess its efficacy and safety for treating refractory or unexplained chronic cough (RCC) in adults.
- Patient eligibility overview: The trial recruits adult patients with refractory or unexplained chronic cough—conditions that have typically proven resistant to standard treatments—representing an unmet clinical need in this patient population.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a randomized placebo-controlled, parallel-arm study to determine the safety and efficacy of SC0032 in participants with RCC
Eligibility Snapshot
- : 1. Males and females between 18 and 80 years. 2. Capable of giving signed informed consent. 3. Diagnosed with RCC (including unexplained chronic cough) for at least 6 months. 4. At least 8 coughs per hour, 24-hour cough frequency during the 14-day Run-In Period. 5. Score ≥ 40 mm on cough severity VAS at Screening. 6. Normal FEV1/FVC ratio of greater than 70% at Screening 7. A negative test for COVID-19. 8. Women of child-bearing potential and men must agree to use a highly effective contraception method during the study and for at least 14 days after the last dose. 9. Willing to carry study-related equipment as required for the study (e.g. cough monitor, phone).
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.